Access to hepatitis C treatment: a lesson for the future

Lucia Craxi', Lucia Craxì

Risultato della ricerca: Articlepeer review


The new generation of direct acting antivirals (DAA) for the treatment of chronic hepatitis C virus infection has revolutionized the previous scenario and has put the institutions under test because of the high cost of therapies. An analysis of what has happened over the last three years, especially in Italy, helps us understand how price negotiation has been managed, and what criteria were chosen at first to allow limited access on the basis of the need of patient care. This allows to focus on some important issues and to identify the challenges ahead in the near future.
Lingua originaleEnglish
pagine (da-a)25-27
Numero di pagine3
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2700???


Entra nei temi di ricerca di 'Access to hepatitis C treatment: a lesson for the future'. Insieme formano una fingerprint unica.

Cita questo